Unique approach of therapeutic immune suppression
Unique approach of therapeutic immune suppression could have implications in immune disease treatment
Scientists have developed a unique approach of therapeutic immune suppression, a discovery that would have have implications for the treatment of diverse immune diseases.
The study, led by Cincinnati Children’s Medical Center, the University of Cincinnati College of Medicine, Medical University of South Carolina, Baylor College of Medicine, Phoenix Children’s Hospital, Children’s National Medical Center, San Francisco School of Medicine, and Nemours Children's Specialty Care, is reported in the Proceedings of the National Academy of Sciences.
Therapeutic immune suppression is an important treatment strategy for many immune conditions, such as autoimmune disorders, immunoregulatory disorders, and in transplantation. Sine immune pathways typically have essential functions in the body, broadly acting drugs and pathway-specific agents may cause severe problems. Thus, antigen-specific immune suppression might be a better option. Now the new research provides a new approach for therapeutic immune suppression, which relies on targeted manipulation of DNA damage in rapidly expanding T cells and allows for highly selective suppression of these cells.
Some immune diseases involve prolonged inflammation and subsequent tissue destruction. The researchers looked at multiple sclerosis (MS) and hemophagocytic lymphohistiocytosis (HLH). MS is an autoimmune disease that occurs when the immune system attacks the myelinated sheaths of neurons, and it is characterized by inflammation in the central nervous system thought to be mediated by autoreactive T cells. HLH is an uncommon but life-threatening syndrome of severe inflammation caused by uncontrolled proliferation of hyperactivated macrophages and lymphocytes. More effective immunosuppressive therapies are needed to improve the prognosis of patients with MS and HLH.
They found that activated mouse and human T cells displayed a pronounced DNA damage-response when they divided rapidly during initial immune responses. According to study leader Michael Jordana, T cells have adapted to rapid division because they are part of the body's defenses against diverse pathogens, but this leads to unusual genomic stress in these cells. The researchers observed that T cells used DNA damage-response pathways to survive. These data suggest that selectively interrupting DNA damage repair in rapidly expanding T cells might be a way to inhibit T cell proliferation.
Since the protein p53 helps initiate DNA damage repair, the researchers decided to target it in T cells. Using preclinical disease models of MS and HLH, they found that potentiation of p53 and impairment of cell cycle checkpoint proteins (CHK1/2 or WEE1) led to the selective elimination of activated, pathological T cells. This approach, named by the researchers as PPCA (p53 potentiation with checkpoint abrogation), could be a therapeutic modality for selective, antigen-specific immune modulation for many immune diseases. Importantly, PPCA therapy did not damage naive, regulatory, or quiescent memory T-cell pools.
If you are finding p53, CHK1/2, and WEE1 proteins and antibodies, or other products like Recombinant MT-ATP8, CusAb can be a good choice.
Scientists have developed a unique approach of therapeutic immune suppression, a discovery that would have have implications for the treatment of diverse immune diseases.
The study, led by Cincinnati Children’s Medical Center, the University of Cincinnati College of Medicine, Medical University of South Carolina, Baylor College of Medicine, Phoenix Children’s Hospital, Children’s National Medical Center, San Francisco School of Medicine, and Nemours Children's Specialty Care, is reported in the Proceedings of the National Academy of Sciences.
Therapeutic immune suppression is an important treatment strategy for many immune conditions, such as autoimmune disorders, immunoregulatory disorders, and in transplantation. Sine immune pathways typically have essential functions in the body, broadly acting drugs and pathway-specific agents may cause severe problems. Thus, antigen-specific immune suppression might be a better option. Now the new research provides a new approach for therapeutic immune suppression, which relies on targeted manipulation of DNA damage in rapidly expanding T cells and allows for highly selective suppression of these cells.
Some immune diseases involve prolonged inflammation and subsequent tissue destruction. The researchers looked at multiple sclerosis (MS) and hemophagocytic lymphohistiocytosis (HLH). MS is an autoimmune disease that occurs when the immune system attacks the myelinated sheaths of neurons, and it is characterized by inflammation in the central nervous system thought to be mediated by autoreactive T cells. HLH is an uncommon but life-threatening syndrome of severe inflammation caused by uncontrolled proliferation of hyperactivated macrophages and lymphocytes. More effective immunosuppressive therapies are needed to improve the prognosis of patients with MS and HLH.
They found that activated mouse and human T cells displayed a pronounced DNA damage-response when they divided rapidly during initial immune responses. According to study leader Michael Jordana, T cells have adapted to rapid division because they are part of the body's defenses against diverse pathogens, but this leads to unusual genomic stress in these cells. The researchers observed that T cells used DNA damage-response pathways to survive. These data suggest that selectively interrupting DNA damage repair in rapidly expanding T cells might be a way to inhibit T cell proliferation.
Since the protein p53 helps initiate DNA damage repair, the researchers decided to target it in T cells. Using preclinical disease models of MS and HLH, they found that potentiation of p53 and impairment of cell cycle checkpoint proteins (CHK1/2 or WEE1) led to the selective elimination of activated, pathological T cells. This approach, named by the researchers as PPCA (p53 potentiation with checkpoint abrogation), could be a therapeutic modality for selective, antigen-specific immune modulation for many immune diseases. Importantly, PPCA therapy did not damage naive, regulatory, or quiescent memory T-cell pools.
If you are finding p53, CHK1/2, and WEE1 proteins and antibodies, or other products like Recombinant MT-ATP8, CusAb can be a good choice.
Report This Post
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.
